- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03287609
EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) (EVOPACS)
August 13, 2019 updated by: University Hospital Inselspital, Berne
EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) - A Randomized, Double-blind, Placebo-controlled Multicenter Study
Reduction of low-density lipoprotein cholesterol (LDL-C) levels effectively reduces the risk of adverse events in patients with established atherosclerotic cardiovascular disease.
The clinical benefit of statins in improving clinical outcomes is proportional to the magnitude of LDL-C reduction, is more pronounced in patients with acute coronary syndromes (ACS) compared with stable coronary artery disease, and emerges at very early stages (as early as 4 weeks) after ACS when statins are administered in the acute phase of the event.
On the basis of this evidence, early initiation of statin therapy is currently recommended in patients presenting with ACS.
Because many patients cannot achieve adequate reduction of LDL-C levels despite treatment with high doses of statins or non-statin lipid-modifying medications, substantial residual risk remains.
Moreover, the time of onset of LDL-C reduction takes 2 weeks following initiation of statin therapy.
Proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors represent a novel class of lipid-lowering drugs leading to rapid, profound, and consistent reductions in LDL-C levels.
While the effectiveness of PCSK9 monoclonal antibodies for LDL-C lowering has been established across patient populations without atherosclerotic cardiovascular disease or with stable ischemic heart disease, reduction and attainment of LDL-C target levels has not been explored in the acute setting of ACS - a clinical setting with highest risk of early event recurrence (within the first month).
In this study the investigators want to evaluate the safety and effectiveness of the PCSK9 inhibitor evolocumab as compared with placebo, administered in the acute phase of ACS, for reduction of LDL-C levels within 8 weeks in patients receiving guideline-recommended high-intensity statin treatment (atorvastatin 40mg QD).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
308
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bern, Switzerland, 3010
- Bern University Hospital
-
-
BS
-
Basel, BS, Switzerland, 4031
- Basel University Hospital
-
-
FR
-
Fribourg, FR, Switzerland, 1708
- HFR Kantonsspital
-
-
GE
-
Geneva, GE, Switzerland, 1211
- Hôpitaux Universitaires Genève
-
-
TI
-
Lugano, TI, Switzerland, 6900
- Cardiocentro Ticino
-
-
VD
-
Lausanne, VD, Switzerland
- Centre Hospitalier Universitaire Vaudois
-
-
ZH
-
Zurich, ZH, Switzerland
- University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Male or female ≥ 18 years of age;
- Hospitalized for a recent ACS;
- LDL-C levels defined as follows:
- LDL-C ≥70 mg/dL (≥1.8 mmol/L) or non-HDL-C ≥100 mg/dL (≥2.6 mmol/) in patients who have been receiving stable treatment with high-intensity statin within ≥ 4 weeks prior to enrollment (i.e. continuous treatment that has not changed with regard to statin intensity over the past 4 weeks) or, LDL-C ≥90 mg/dL (≥2.3 mmol/L) or non-HDL-C ≥120 mg/dL (≥3.1 mmol/) in patients who have been receiving stable treatment with low- or moderate-intensity statin within ≥ 4 weeks prior to enrollment (i.e. continuous treatment that has not changed with regard to statin intensity over the past 4 weeks), or LDL-C ≥125 mg/dL (≥3.2 mmol/L) or non-HDL-C ≥155 mg/dL (≥4.0 mmol/) in patients who are statin-naïve or have not been on a stable (unchanged) statin regimen for at least 4 weeks prior to enrollment;
- Ability to understand the requirements of the study and to provide informed consent.
Exclusion Criteria:
- Unstable clinical status (hemodynamic or electrical instability;
- Uncontrolled cardiac arrhythmia, defined as recurrent and symptomatic ventricular tachycardia or atrial fibrillation with rapid ventricular response not controlled by medications in the past 3 months prior to screening;
- Severe renal dysfunction, defined by estimated glomerular filtration rate <30 ml/min/1.73m2;
- Active liver disease or hepatic dysfunction, either reported in patient medical record or defined by asparate aminotransferase (AST) or alanine aminotransferase (ALT) levels > 3x the upper limit of normal;
- Reported intolerance to atorvastatin (any dose) OR statin intolerance;
- Known allergy to contrast medium, heparin, aspirin, ticagrelor or prasugrel;
- Known sensitivity to any substances to be administered;
- Patients who previously received evolocumab or other PCSK9 inhibitor;
- Patient who received cholesterol ester transfer protein inhibitors in the past 12 months prior to screening;
- Treatment with systemic steroids or systemic cyclosporine in the past 3 months systemic cyclosporine, systemic steroids (eg. intravenous, intramuscular or per os);
- Known active infection or major hematologic, metabolic, or endocrine dysfunction in the judgment of the Investigator;
- Patients who will not be available for study-required procedures in the judgment of the Investigator;
- Current enrollment in another investigational device or drug study;
- Active malignancy requiring treatment;
- Female of childbearing potential (age <50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Evolocumab
Evolocumab 140 mg/mL, pre-filled auto-injector pen, 3 injections at day 1 and week 4
|
Three injections with pre-filled auto-injector pen at day 1 and at week 4.
|
Placebo Comparator: Placebo
Placebo, pre-filled auto-injector pen, 3 injections at day 1 and week 4
|
Three injections with pre-filled auto-injector pen at day 1 and at week 4.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent change in calculated LDL-C in the intent to treat (ITT) population
Time Frame: Baseline to week 8
|
Baseline to week 8
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients with adverse events and serious adverse events
Time Frame: Baseline to week 8
|
Baseline to week 8
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nominal change in calculated LDL-C
Time Frame: Baseline to week 8
|
Baseline to week 8
|
|
Proportion of patients with LDL-C level <70 mg/dL (<1.8 mmol/L) at week 8
Time Frame: Baseline to week 8
|
Baseline to week 8
|
|
Change in total cholesterol in the ITT population
Time Frame: Baseline to week 8
|
Baseline to week 8
|
|
Change in HDL-C in the ITT population
Time Frame: Baseline to week 8
|
Baseline to week 8
|
|
Change in lipoprotein-a in the ITT population
Time Frame: Baseline to week 8
|
Baseline to week 8
|
|
Change in triglycerides in the ITT population
Time Frame: Baseline to week 8
|
Baseline to week 8
|
|
Change in non-HDL-C in the ITT population
Time Frame: Baseline to week 8
|
Baseline to week 8
|
|
Change in apolipoprotein B in the ITT population
Time Frame: Baseline to week 8
|
Baseline to week 8
|
|
Change in apolipoprotein A-1 in the ITT population
Time Frame: Baseline to week 8
|
Baseline to week 8
|
|
Percent change in high-sensitivity CRP (hs-CRP) in the ITT population
Time Frame: Baseline to week 8
|
Baseline to week 8
|
|
Proportion of patients with hs-CRP level <2 mg/dL at week 8 in the ITT population
Time Frame: Baseline to week 8
|
Baseline to week 8
|
|
Proportion of patients with LDL-C <70 mg/dL and hs-CRP <2 mg/dL at week 8 in the ITT population
Time Frame: Baseline to week 8
|
Baseline to week 8
|
|
Nominal change in Interleukin (IL)-1b and IL-6 in the ITT population
Time Frame: Baseline to week 8
|
Baseline to week 8
|
|
Change in high-sensitivity Troponin T
Time Frame: Baseline to 72 hours
|
Baseline to 72 hours
|
|
Area under the curve (AUC) at Multiplate with Adenosinediphosphate (ADP) test
Time Frame: Baseline to 72 hours and to week 8
|
Platelet inhibition assessed with Multiplate ADP test at 72 hours and 8 weeks
|
Baseline to 72 hours and to week 8
|
Area under the curve (AUC) at Multiplate with Thrombin receptor activating peptide (TRAP) test
Time Frame: Baseline to 72 hours and to week 8
|
Platelet inhibition assessed with Multiplate TRAP test at 72 hours and 8 weeks
|
Baseline to 72 hours and to week 8
|
Number of patients with contrast-induced acute kidney injury (CI-AKI) at 72 hours among patients who undergo coronary angiography at baseline
Time Frame: Baseline to 72 hours
|
Baseline to 72 hours
|
|
Number of patients with adjudicated events (death, cardiovascular death, myocardial infarction, hospitalization for recurrent ACS, hospitalization for heart failure, coronary revascularization, stroke
Time Frame: Baseline to week 8
|
Baseline to week 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Stephan Windecker, Prof., MD, Bern University Hospital
- Principal Investigator: Konstantinos Koskinas, MD, Bern University Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
- Lipinski MJ, Benedetto U, Escarcega RO, Biondi-Zoccai G, Lhermusier T, Baker NC, Torguson R, Brewer HB Jr, Waksman R. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J. 2016 Feb 7;37(6):536-45. doi: 10.1093/eurheartj/ehv563. Epub 2015 Nov 17.
- Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E; PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005 Oct 18;46(8):1405-10. doi: 10.1016/j.jacc.2005.03.077.
- Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001 Apr 4;285(13):1711-8. doi: 10.1001/jama.285.13.1711.
- Navarese EP, Kolodziejczak M, Kereiakes DJ, Tantry US, O'Connor C, Gurbel PA. Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review. Ann Intern Med. 2016 May 3;164(9):600-7. doi: 10.7326/M15-2994. Epub 2016 Mar 22.
- Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, Muller O, Haner J, Gencer B, Crljenica C, Amini P, Deckarm O, Iglesias JF, Raber L, Heg D, Mach F. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). J Am Coll Cardiol. 2019 Nov 19;74(20):2452-2462. doi: 10.1016/j.jacc.2019.08.010. Epub 2019 Aug 31.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 23, 2018
Primary Completion (Actual)
May 20, 2019
Study Completion (Actual)
August 7, 2019
Study Registration Dates
First Submitted
September 7, 2017
First Submitted That Met QC Criteria
September 14, 2017
First Posted (Actual)
September 19, 2017
Study Record Updates
Last Update Posted (Actual)
August 14, 2019
Last Update Submitted That Met QC Criteria
August 13, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-01753
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
No plan to make individual participant data available to other researchers
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Coronary Syndrome
-
Yonsei UniversityRecruitingCoronary Artery Disease, Acute Coronary SyndromeKorea, Republic of
-
Meditrix CorpNational University of Ireland, Galway, Ireland; Boston Scientific Japan K.K.; Fujita Health UniversityRecruitingChronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromeJapan, Ireland
-
OrbusNeichDuke Clinical Research Institute; OrbusNeich Medical K.K.CompletedCoronary Arteriosclerosis | Non ST Segment Elevation Acute Coronary SyndromeUnited States, Japan
-
Medical University of WarsawRecruitingAcute Coronary Syndrome | Chronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromePoland
-
Niguarda HospitalCompletedAcute Coronary Syndrome With ST Elevation on Electrocardiogram | Acute Coronary Syndrome Without ST Elevation on Electrocardiogram | Noncritical Coronary Artery Disease Coronary Stenosis Less Than 50 Per Cent | Aortic AneurysmsItaly
-
Sohag UniversityRecruitingLeft Main Coronary Artery Disease With Acute Coronary SyndromeEgypt
-
Eli Lilly and CompanyDaiichi Sankyo, Inc.CompletedCoronary Arteriosclerosis | Acute Coronary SyndromesUnited States
-
University of PatrasCompletedCoronary Artery Disease (CAD) | Acute Coronary Syndrome (ACS)Greece
-
Deutsches Herzzentrum MuenchenDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)CompletedAcute Coronary Syndrome (ACS)Germany, Italy
-
Northwestern UniversityTerminatedACS - Acute Coronary SyndromeUnited States
Clinical Trials on Evolocumab 140 mg/mL
-
First Affiliated Hospital Xi'an Jiaotong UniversityCompleted
-
University Hospital, GrenobleRecruiting
-
Radboud University Medical CenterAmgenRecruitingCoronary Artery Disease | Atherosclerosis of Coronary ArteryNetherlands
-
University of Campinas, BrazilCompletedDiabetes Mellitus, Type 2 | Dyslipidemia Associated With Type II Diabetes Mellitus | Hypertension ArterialBrazil
-
Wuhan Union Hospital, ChinaRecruitingHigh-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized StudyCerebral AtherosclerosisChina
-
Leonardo ClavijoAmgenUnknownPeripheral Arterial DiseaseUnited States
-
Assistance Publique - Hôpitaux de ParisAmgen; Action Research GroupRecruitingNSTEMI - Non-ST Segment Elevation MI | STEMI - ST Elevation Myocardial InfarctionFrance
-
Henan Institute of Cardiovascular EpidemiologyRecruitingST Elevation Myocardial Infarction (STEMI)China
-
Merck Sharp & Dohme LLCTerminated
-
Novo Nordisk A/SCompletedAtherosclerotic Cardiovascular DiseaseGermany, Poland, United States, Netherlands, Japan, Greece, Belgium